Fed Circ. Revives Mylan Bid To Invalidate Relistor Patent
The Federal Circuit revived a Mylan Pharmaceuticals Inc. bid to invalidate the patent for opioid-induced constipation drug Relistor, ruling Wednesday that a lower court was too hasty in finding that the...To view the full article, register now.
Already a subscriber? Click here to view full article